All Journal Guides

Journal Guide

Nature Immunology Impact Factor 27.6: Publishing Guide

The Nature home for fundamental immunology: where professional editors and 5-day decisions meet the highest-impact immune discoveries

27.6

Impact Factor (2024)

~5-8%

Acceptance Rate

5 days median to first editorial decision

Time to First Decision

What Nature Immunology Publishes

Nature Immunology publishes high-impact papers across immunology, prioritizing work that delivers fundamental insight into how the immune system works while increasingly welcoming strong translational studies. It currently edges Immunity on 2024 JIF (27.6 vs. 26.3) and is distinguished by an all-professional editorial team with no external editorial board, so editorial decisions are made fully in house.

  • Innate immunity: pattern recognition, inflammasomes, innate lymphoid cells
  • Adaptive immunity: T cell and B cell biology, antibody responses, antigen presentation
  • Tumor immunology and cancer immunotherapy mechanisms
  • Autoimmunity, immune tolerance, and transplantation
  • Infectious disease immunology and microbial immunopathology
  • Neuroimmunology, immunometabolism, and mucosal immunity (expanding scope)

Editor Insight

Nature Immunology and Immunity are the two preeminent specialist immunology journals, and Nature Immunology currently holds the IF edge (27.6 vs 26.3). The fundamental difference is editorial philosophy: Nature Immunology uses all-professional editors with no academic board, producing fast and consistent decisions. The 5-day median first decision respects authors' time. The Letter format offers a home for important findings that do not need full Article treatment. If your work provides fundamental insight into immune function with broad significance, this is the right venue.

What Nature Immunology Editors Look For

Fundamental insight into immune function

The core criterion: does your paper advance understanding of HOW the immune system works? Not phenomenology, not observation - mechanistic understanding at molecular, cellular, or organism level.

Translational relevance (increasingly important)

The editors explicitly expanded scope to welcome translational and human/clinical immunology. Human data strengthens any submission. Papers connecting basic immunology to disease mechanisms get extra consideration.

Broad significance across immunology

Must interest immunologists beyond your specific subfield. A paper on dendritic cells should intrigue a T cell biologist. Work on mucosal immunity should interest a tumor immunologist.

Novelty that advances the field significantly

Incremental findings do not clear the bar. Your paper needs to change how immunologists think about a problem, not just add data points to an established framework.

Technical rigor with appropriate evidence

Sound conclusions supported by well-controlled experiments. Statistical rigor, reproducibility, and appropriate use of biological replicates are expected.

Mechanistic depth, not just descriptive phenotyping

Identifying a new immune cell state is the starting point. Explaining the molecular machinery driving that state is what Nat Immunol wants.

Why Papers Get Rejected

These patterns appear repeatedly in manuscripts that don't make it past Nature Immunology's editorial review:

Insufficient novelty - incremental findings

The most common desk rejection reason. With 75-85% desk rejection and a 5-day decision, papers that do not immediately communicate a significant advance are turned away fast.

Too narrow scope for the broad immunology readership

Nature Immunology serves ALL immunologists. A paper of interest only to the 30 people studying one specific receptor will not clear editorial screening.

Descriptive phenotyping without mechanistic follow-up

scRNA-seq showing immune cell states in a disease model is not enough. What drives those states? What happens when you perturb them? Mechanism is non-negotiable.

Poor communication of significance in cover letter and abstract

Professional editors evaluate papers across all immunology subfields. If the cover letter does not clearly articulate why your finding matters broadly, it cannot be effectively assessed.

Missing Reporting Summary Checklist

Required within 48 hours of peer review notification. Failing to provide it delays the process and signals lack of familiarity with Nature journal procedures.

Resubmitting after rejection without formal appeal

Editors explicitly warn against revising and resubmitting rejected papers without first consulting via formal appeal. Simply addressing technical points may not address the conceptual concerns behind rejection.

Does your manuscript avoid these patterns?

The quick diagnostic reads your full manuscript against Nature Immunology's criteria and flags the specific issues most likely to cause rejection.

Run Free Readiness Scan →

Insider Tips from Nature Immunology Authors

5-day median first decision is among the fastest at elite journals

A fast 'no' is a gift - it lets you pivot to Immunity, Science Immunology, or JEM within a week. A positive response means editors are seriously interested. Either way, you waste less time.

The Nature transfer cascade is a massive ecosystem advantage

Rejected papers can transfer to Nature Communications, Communications Biology, or Scientific Reports carrying peer review history. The receiving journal may accept without further review if technically sound.

No external editorial board means consistent decisions

Unlike Immunity (which uses academic editors), Nature Immunology decisions are made entirely by ~6 professional editors. No potential conflicts from academic board members reviewing competitors' work.

The Letter format is an underused competitive advantage

Nature Immunology publishes shorter Letter papers (2,500 words, 5 display items). Perfect for high-impact findings that do not need a full Article. Many authors overlook this option.

Double-blind peer review is available as an opt-in

Available since 2015. Reviewers will not know who the authors are. Useful for early-career researchers or those from less well-known institutions who want to remove potential name bias.

Presubmission enquiries save months

Submit only an abstract through the Manuscript Tracking System. Quick turnaround (typically within a week). A positive response is encouraging but not a guarantee. A negative response saves you months.

Resource papers are a growing opportunity

Explicit format for large datasets (scRNA-seq atlases, proteomics). As immunology becomes more data-driven, Resource papers face less competition than Article/Letter formats.

Transparent peer review is available as an author opt-in

You can choose to publish anonymous reviewer reports alongside your paper. Growing uptake demonstrates transparency and helps the community understand editorial standards.

The Nature Immunology Submission Process

1

Presubmission enquiry (recommended for scope questions)

Response within ~1 week

Submit an abstract only (NOT full manuscript) through the Manuscript Tracking System. Editors indicate whether the work is in scope.

2

Full submission via MTS

Quality check in 1-2 days

Complete manuscript with cover letter, Reporting Summary Checklist, Editorial Policy Checklist. Decide on double-blind review opt-in. Deposit large datasets in public repositories.

3

Editorial assessment

5 days median to first decision

Assigned to one of ~6 professional editors. No external editorial board. Editor reads paper, consults team. ~75-85% desk rejected. Advance, soundness, evidence quality, and broad relevance assessed.

4

Peer review

4-8 weeks typical

2-3 reviewers with relevant expertise. Anonymous to authors unless reviewer self-identifies. Reporting Summary required within 48 hours of review notification.

5

Revision

1-3 months typically given

Point-by-point response to all reviewer and editor comments. Papers can still be rejected for novelty/interest after addressing all technical points.

6

Publication

~300 days total; 2-4 weeks from acceptance to online

Developmental editing by editors for readability. Monthly publication (12 issues/year). Total submission to acceptance: ~300 days median.

Nature Immunology by the Numbers

2024 Impact Factor(Clarivate JCR; outranks Immunity (26.3))27.6
5-Year Impact Factor29.2
CiteScore(Scopus)32.7
H-index424
Median to first editorial decision5 days
Median submission to acceptance300 days
Annual downloads7.0 million
Monthly publication12 issues/year

Before you submit

Nature Immunology accepts a small fraction of submissions. Make your attempt count.

The pre-submission diagnostic runs a live literature search, scores your manuscript section by section, and gives you a prioritized fix list calibrated to Nature Immunology. ~30 minutes.

Article Types

Article

3,000-4,000 words, up to 8 items

Substantial novel research divided into Introduction, Results, Discussion, and Online Methods.

Letter

~2,500 words, up to 5 display items

Important but less extensive findings. No headings except Methods. Shorter format for focused discoveries.

Resource

3,000-4,000 words, up to 8 items

Large datasets of broad utility to the immunology community (scRNA-seq atlases, proteomics).

Review / Perspective

3,000-4,000 words, up to 100 references

Authoritative surveys or scholarly opinion pieces. Reviews must not be dominated by the authors' own work.

Landmark Nature Immunology Papers

Papers that defined fields and changed science:

  • Foxp3 programs regulatory T cell development (Fontenot, Gavin & Rudensky, 2003)
  • NLRP3 inflammasome and cGAS-STING pathway landmark papers
  • Innate Lymphoid Cell classification and early characterization
  • Founding Th17 cell biology and differentiation papers
  • 20th anniversary collection: landmarks in innate immunity, T cell education, and cancer immune evasion (2020)

Preparing a Nature Immunology Submission?

Get pre-submission feedback from reviewers who've published in Nature Immunology and know exactly what editors look for.

Run Free Readiness Scan

Need expert depth? Human review from $1,000

NDA-protected
Confidential

Primary Fields

Innate Immunity & InflammationT Cell & B Cell BiologyTumor ImmunologyAutoimmunity & ToleranceInfectious Disease ImmunologyNeuroimmunology